Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Trinity Biotech (TRIB) over the last 14 years, with Q2 2025 value amounting to $83.6 million.

  • Trinity Biotech's Non-Current Debt rose 2709.96% to $83.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $83.6 million, marking a year-over-year increase of 2709.96%. This contributed to the annual value of $72.4 million for FY2024, which is 8048.57% up from last year.
  • Trinity Biotech's Non-Current Debt amounted to $83.6 million in Q2 2025, which was up 2709.96% from $72.4 million recorded in Q4 2024.
  • Trinity Biotech's 5-year Non-Current Debt high stood at $83.6 million for Q2 2025, and its period low was $39.8 million during Q2 2023.
  • In the last 4 years, Trinity Biotech's Non-Current Debt had a median value of $49.2 million in 2023 and averaged $55.7 million.
  • In the last 5 years, Trinity Biotech's Non-Current Debt crashed by 3547.33% in 2023 and then surged by 8048.57% in 2024.
  • Over the past 4 years, Trinity Biotech's Non-Current Debt (Quarter) stood at $44.3 million in 2022, then fell by 9.46% to $40.1 million in 2023, then surged by 80.49% to $72.4 million in 2024, then increased by 15.54% to $83.6 million in 2025.
  • Its Non-Current Debt was $83.6 million in Q2 2025, compared to $72.4 million in Q4 2024 and $66.4 million in Q3 2024.